News
Building on an existing relationship through Catalyst's Propel Partner Program, Catalyst has been providing installation, ...
Astria Therapeutics' Navenibart shows promise in phase 3 trials for hereditary angioedema. Click here to find out why ATXS ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback